New York-based Pfizer is expected to pay at least $60 million to the United States to settle allegations that it paid bribes to companies overseas to obtain business, according to a Wall Street Journal report.
In a Nov. 10 regulatory filing, Pfizer said it had reached agreements in principle with the Securities Exchange Commission and Department of Justice regarding “potentially improper payments” made by Pfzier and Wyeth, a subsidiary Pfizer acquired in 2009. The settlement has not been finalized and the terms could change, according to the report. It is also unclear whether Pfizer or Wyeth will admit to wrongdoing.
In April, Pfizer competitor Johnson & Johnson agreed to pay $70 million to resolve similar allegations that its subsidiaries paid bribes to Greek physicians in exchange for their business, according to the report.
Related Articles on Pharmaceutical Companies and Settlements:
Investigators Want Information on Merck’s Marketing Practices
GlaxoSmithKline Settles Case Over Drug Pricing, Marketing With $3B
Pfizer Resolves False Claims Allegations With $14.5M Settlement
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
